VKTX - Lipocine: Imminent Catalysts In NASH And Oral Testosterone Replacement Therapy Make For A Strong Buy

• LPCN’s long road to market for its oral testosterone pill has been bumpy; however, the FDA just gave TLANDO tentative approval.
• LPCN traded down on the approval, but traders are missing out on the bigger picture: the company's promising drug candidate in NASH, and a market with a massive unmet need.
• LPCN's top-line Phase II results of LPCN 1144 in NASH are mere weeks away from being released.
• What's more, LPCN's patent infringement lawsuit against Clarus Pharmaceuticals goes to jury trial in February 2021. LPCN already crushed Clarus in a previous lawsuit by Clarus against LPCN, which even led to Clarus' own oral testosterone patent being invalidated.
• With many positive catalysts coming within weeks, now is an excellent time to stock up on the shares.

For further details see: